Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)-Reference-Cited by-同舟云学术

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)

Published:2015-06-08 Issue:1 Volume:75 Page:68-74
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Burmester Gerd R,Rubbert-Roth Andrea,Cantagrel Alain,Hall Stephen,Leszczynski Piotr,Feldman Daniel,Rangaraj Madura J,Roane Georgia,Ludivico Charles,Bao Min,Rowell Lucy,Davies Claire,Mysler Eduardo F

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference13 articles.

1. Biologic agents in rheumatoid arthritis: an update for managed care professionals;Agarwal;J Manag Care Pharm,2011

2. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis;Huynh;Patient Prefer Adherence,2014

3. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy;Barton;Patient Prefer Adherence,2009

4. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial;Smolen;Lancet,2008

5. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study;Genovese;Arthritis Rheum,2008

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching from intravenous to subcutaneous tocilizumab for uveitis during the COVID-19 pandemic: a case series;Canadian Journal of Ophthalmology;2024-08

2. The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy;Journal of Infection and Public Health;2024-06

3. Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis;Rheumatology;2024-03-29

4. Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open‐Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission;Arthritis & Rheumatology;2024-01-25

5. Advancing Subcutaneous Dosing Regimens for Biotherapeutics: Clinical Strategies for Expedited Market Access;BioDrugs;2023-10-13